185 related articles for article (PubMed ID: 34096864)
1. Psoriatic Alopecia in a Patient With Crohn Disease: An Uncommon Manifestation of Tumor Necrosis Factor α Inhibitors.
Carrasquillo OY; Pabón-Cartagena G; Barrera-Llaurador J; Colón-Fontanez F; Martín-García RF
Cutis; 2021 Apr; 107(4):E48-E55. PubMed ID: 34096864
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab-induced scalp psoriasis with severe alopecia.
Özkur E; Altunay İK; Leblebici C; Topkarcı Z; Erdem Y
Dermatol Ther; 2019 Sep; 32(5):e13033. PubMed ID: 31350777
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
Wollina U; Hansel G; Koch A; Schönlebe J; Köstler E; Haroske G
Am J Clin Dermatol; 2008; 9(1):1-14. PubMed ID: 18092839
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab-induced psoriatic alopecia/alopecia areata-like reaction in a patient with Crohn's disease.
Toda-Brito H; Lopes L; Soares-Almeida L; Filipe P
Dermatol Online J; 2015 Nov; 21(11):. PubMed ID: 26632930
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor-induced alopecia: alternative pathology and therapy.
Udkoff J; Cohen PR
Dermatol Online J; 2017 Jun; 23(6):. PubMed ID: 28633753
[TBL] [Abstract][Full Text] [Related]
6. Paradoxical Psoriasiform Eruptions in Children Receiving Tumor Necrosis Factor α Inhibitors.
Eickstaedt J; Paller AS; Lund E; Murphrey M; Brandling-Bennett H; Maurano M; Fernandez Faith E; Holland KE; Ibler E; Liang MG; Todd PS; Siegfried E; Igelman S; Cordoro KM; Tollefson MM
JAMA Dermatol; 2023 Jun; 159(6):637-642. PubMed ID: 37043214
[TBL] [Abstract][Full Text] [Related]
7. Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients.
Peer FC; Miller A; Pavli P; Subramaniam K
Intern Med J; 2017 Dec; 47(12):1445-1448. PubMed ID: 29224199
[TBL] [Abstract][Full Text] [Related]
8. Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab.
Andrisani G; Marzo M; Celleno L; Guidi L; Papa A; Gasbarrini A; Armuzzi A
Eur Rev Med Pharmacol Sci; 2013 Oct; 17(20):2831-6. PubMed ID: 24174369
[TBL] [Abstract][Full Text] [Related]
9. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
[TBL] [Abstract][Full Text] [Related]
10. Persistent neutrophilic scarring alopecia triggered by anti-TNF blockade for Crohn's disease.
Amschler K; Mc Broekaert S; Mohr J; Schön MP; Mößner R
Eur J Dermatol; 2018 Jun; 28(3):403-405. PubMed ID: 29976546
[No Abstract] [Full Text] [Related]
11. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
Weizman AV; Sharma R; Afzal NM; Xu W; Walsh S; Stempak JM; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
Dig Dis Sci; 2018 Sep; 63(9):2430-2438. PubMed ID: 29736839
[TBL] [Abstract][Full Text] [Related]
12. Alopecia secondary to anti-tumor necrosis factor-alpha therapy.
Ribeiro LB; Rego JC; Estrada BD; Bastos PR; Piñeiro Maceira JM; Sodré CT
An Bras Dermatol; 2015; 90(2):232-5. PubMed ID: 25830994
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab-related alopecia in a patient affected by psoriasis.
Melé-Ninot G; Expósito-Serrano V; Quintana Codina M; Iglesias Sancho M; Sánchez-Regaña M; Umbert Millet P; Salleras Redonnet M
Dermatol Online J; 2017 Jul; 23(7):. PubMed ID: 29469696
[TBL] [Abstract][Full Text] [Related]
14. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
Bae JM; Lee HH; Lee BI; Lee KM; Eun SH; Cho ML; Kim JS; Park JM; Cho YS; Lee IS; Kim SW; Choi H; Choi MG
Aliment Pharmacol Ther; 2018 Jul; 48(2):196-205. PubMed ID: 29869804
[TBL] [Abstract][Full Text] [Related]
15. Skin Manifestations in Pediatric Patients Treated With a TNF-Alpha Inhibitor for Inflammatory Bowel Disease: A Retrospective Study [Formula: see text].
Cossio ML; Genois A; Jantchou P; Hatami A; Deslandres C; McCuaig C
J Cutan Med Surg; 2020; 24(4):333-339. PubMed ID: 32527153
[TBL] [Abstract][Full Text] [Related]
16. TNF-inhibitor associated psoriatic alopecia: Diagnostic utility of sebaceous lobule atrophy.
Afanasiev OK; Zhang CZ; Ruhoy SM
J Cutan Pathol; 2017 Jun; 44(6):563-569. PubMed ID: 28332233
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.
Kip KE; Swoger JM; Grandinetti LM; Barrie AM; Greer JB; Regueiro MD
Inflamm Bowel Dis; 2013 May; 19(6):1164-72. PubMed ID: 23518804
[TBL] [Abstract][Full Text] [Related]
18. Paradoxical psoriasis in pediatric patients: A systematic review.
Cyrenne BM; Parpia AS; Sibbald C
Pediatr Dermatol; 2021 Sep; 38(5):1086-1093. PubMed ID: 34402108
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor-α inhibitor-induced psoriasis in juvenile idiopathic arthritis patients.
Groth D; Perez M; Treat JR; Castelo-Soccio L; Nativ S; Weiss PF; Lapidus S; Perman MJ
Pediatr Dermatol; 2019 Sep; 36(5):613-617. PubMed ID: 31240749
[TBL] [Abstract][Full Text] [Related]
20. Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis.
Vasconcellos JB; Pereira DD; Vargas TJ; Levy RA; Pinheiro GD; Cursi ÍB
An Bras Dermatol; 2016; 91(5 suppl 1):137-139. PubMed ID: 28300922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
